Dr. Burtness on Immunotherapy and Chemotherapy in Head and Neck Cancer

Video

Barbara Burtness, MD, professor of Medicine, Yale Cancer Center, discusses the potential benefits of using immunotherapy and chemotherapy together in head and neck cancer.

Barbara Burtness, MD, professor of Medicine, Yale Cancer Center, discusses the potential benefits of using immunotherapy and chemotherapy together in head and neck cancer.

While it unknown if the combination is synergistic, would not necessarily even need to be to be beneficial, says Burtness. A patient could get an independent benefit from immunotherapy and from chemotherapy at the same time, providing the reliability of the chemotherapy response and the durability of the immunotherapy response together.

However, there may be some synergy. Chemotherapy causes DNA damage and cell death and, as the cells die, they release antigens. This creates mutations that may lead to novel antigens. The possibility that there really could be a uniquely synergistic effect, where each drug amplifies the benefit of the other, is very intriguing, says Burtness.

Related Videos
Jorge J. Castillo, MD,
Heinz-Josef Lenz, MD, FACP
Sundar Jagannath, MBBS, director, Center of Excellence for Multiple Myeloma, professor of medicine (hematology and medical oncology), The Tisch Cancer Institute, Mount Sinai
Omid Hamid, MD, professor, medicine, Cedars-Sinai; director, Clinical Research and Immunotherapy, director, Cutaneous Oncology and Melanoma, The Angeles Clinic and Research Institute
Christina L. Roland, MD, MS, FACS
Ashish Saxena, MD, PhD
Shruti Tiwari, MD
Scott Kopetz, MD, PhD, FACP
Katharina Hoebel, MD, PhD
Catherine C. Coombs, MD, associate clinical professor, medicine, University of California, Irvine School of Medicine